CSL’s shares (ASX: CSL) have started the year with the bears leading the way, with a 0.26% decline today bringing the cumulative YTD loss to 8.86%. With a new 52 week low of $253.04 being hit on the day, this continues the trend seen towards the second half of 2024, where the share price fell some 10% in the last five months of the year.
With the stock not having traded around these levels since 2023, you have to look back to find areas of support. With $260 broken to the downside, $248 could be the next level to watch.
Holders were looking for some positivity coming out of interim results for 2025, with the reveal coming in slightly more mixed.
The results show that vaccine hesitancy is an increasing challenge in the US, driven by factors such as misinformation, distrust in public institutions, and COVID-19 fatigue. This scepticism extends beyond COVID-19, impacting routine vaccinations like flu shots. These societal issues pose ongoing challenges for pharmaceutical companies operating in this space.
CSL Behring, a key division of the company, continues to demonstrate robust growth. This division’s success is critical for the overall performance of CSL, given its focus on therapies that treat rare and serious diseases. Strong performance in this segment indicates positive momentum despite external challenges.
Top Australian Brokers
- City Index - Aussie shares from $5 - Read our review
- Pepperstone - Trading education - Read our review
- IC Markets - Experienced and highly regulated - Read our review
- eToro - Social and copy trading platform - Read our review
CSL’s 2025 interim results underscore strong growth prospects, particularly within its Behring division, amidst challenges like rising vaccine hesitancy in the US. The financial performance is presented with transparency regarding fees and performance considerations, aiding in informed investment decisions.
Don’t Buy Just Yet
You will want to see this before you make any decisions.
Before you decide which shares to add to your portfolio you might want to take a look at this special report we recently published.
Our experts picked out The 5 best ASX shares to buy in 2024.
We’re giving away this valuable research for FREE.
Click below to secure your copy
